{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:00:01Z","timestamp":1790402401913,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-025-02782-7","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T09:15:43Z","timestamp":1739178943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The efficacy and safety of bivalirudin and heparin in patients with acute coronary syndrome: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-5191","authenticated-orcid":false,"given":"You","family":"Zhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6628-354X","authenticated-orcid":false,"given":"Hongcai","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"2782_CR1","doi-asserted-by":"publisher","first-page":"H583","DOI":"10.1152\/ajpheart.00239.2014","volume":"308","author":"CC Leonardo","year":"2015","unstructured":"Leonardo CC, Mendes M, Ahmad AS, Dore S. Efficacy of prophylactic flavan-3-ol in permanent focal ischemia in 12-mo-old mice. Am J Physiol Heart Circ Physiol. 2015;308:H583\u201391.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2782_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2015.10.044","volume":"67","author":"L Anderson","year":"2016","unstructured":"Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: cochrane systematic review and meta-analysis. J Am Coll Cardiol. 2016;67:1\u201312.","journal-title":"J Am Coll Cardiol"},{"key":"2782_CR3","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/jama.2015.10945","volume":"314","author":"CK Chow","year":"2015","unstructured":"Chow CK, Redfern J, Hillis GS, Thakkar J, Santo K, Hackett ML, et al. Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: a randomized clinical trial. JAMA. 2015;314:1255\u201363.","journal-title":"JAMA"},{"key":"2782_CR4","first-page":"CD008895","volume":"6","author":"L Anderson","year":"2017","unstructured":"Anderson L, Brown JP, Clark AM, Dalal H, Rossau HK, Bridges C, et al. Patient education in the management of coronary heart disease. Cochrane Database Syst Rev. 2017;6:CD008895.","journal-title":"Cochrane Database Syst Rev"},{"key":"2782_CR5","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1161\/01.STR.0000170642.39876.f2","volume":"36","author":"RG Hart","year":"2005","unstructured":"Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005;36:1588\u201393.","journal-title":"Stroke"},{"key":"2782_CR6","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"SR Steinhubl","year":"2002","unstructured":"Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411\u201320.","journal-title":"JAMA"},{"key":"2782_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/ehjqcco\/qcac031","volume":"9","author":"OM Dong","year":"2023","unstructured":"Dong OM, Friede KA, Chanfreau-Coffinier C, Voora D. Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in veterans undergoing percutaneous coronary intervention for acute coronary syndromes. Eur Heart J Qual Care Clin Outcomes. 2023;9:249\u201357.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2782_CR8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/ijs.12452","volume":"10","author":"K Toyoda","year":"2015","unstructured":"Toyoda K, Arihiro S, Todo K, Yamagami H, Kimura K, Furui E, et al. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study. Int J Stroke. 2015;10:836\u201342.","journal-title":"Int J Stroke"},{"key":"2782_CR9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/bmj.313.7058.652","volume":"313","author":"R Collins","year":"1996","unstructured":"Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ. 1996;313:652\u20139.","journal-title":"BMJ"},{"key":"2782_CR10","first-page":"982","volume":"32","author":"X Feng","year":"2020","unstructured":"Feng X, Deng L, Zhang Y, Chang L. [Regional citrate versus heparin anticoagulation in continuous renal replacement therapy in critically ill patients: a meta-analysis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32:982\u20137.","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"2782_CR11","doi-asserted-by":"publisher","first-page":"R275","DOI":"10.1186\/cc10556","volume":"15","author":"M Ranucci","year":"2011","unstructured":"Ranucci M, Ballotta A, Kandil H, Isgro G, Carlucci C, Baryshnikova E, et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care. 2011;15:R275.","journal-title":"Crit Care"},{"key":"2782_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40:87\u2013165.","journal-title":"Eur Heart J"},{"key":"2782_CR13","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.21037\/jtd.2017.10.23","volume":"9","author":"IY Elgendy","year":"2017","unstructured":"Elgendy IY, Capodanno D. Heparin versus bivalirudin for percutaneous coronary intervention: has the debate come to an end? J Thorac Dis. 2017;9:4305\u20137.","journal-title":"J Thorac Dis"},{"key":"2782_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.carrev.2023.11.008","volume":"61","author":"M Cohen","year":"2024","unstructured":"Cohen M, Sohal S. Editorial: bivalirudin versus unfractionated heparin in acute myocardial infarction: why are we still debating? Cardiovasc Revasc Med. 2024;61:62\u20133.","journal-title":"Cardiovasc Revasc Med"},{"key":"2782_CR15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jacc.2014.07.523","volume":"64","author":"MM Ansari","year":"2014","unstructured":"Ansari MM, Garcia DC, Toussaint JL, Mendoza C, Alfonso C, Cohen MG, et al. Comparison of bivalirrudin and heparin use for acute myocardial infarction: a meta-analysis of the randomized trials. J Am Coll Cardiol. 2014;64:460\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"2782_CR16","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane handbook for systematic reviews of interventions version 6.5 (updated August 2024). Cochrane; 2024. Available from www.training.cochrane.org\/handbook."},{"key":"2782_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"2782_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.carrev.2024.03.025","volume":"66","author":"E Omerovic","year":"2024","unstructured":"Omerovic E, James S, R\u00e5mundal T, Fr\u00f6bert O, Linder R, Danielewicz M, et al. Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction-outcomes at two years. Cardiovasc Revasc Med. 2024;66:43\u201350.","journal-title":"Cardiovasc Revasc Med"},{"key":"2782_CR19","first-page":"140","volume":"42","author":"H Song","year":"2023","unstructured":"Song H, Sun Y, Liu M. Comparison of the application effect and safety of bivalirudin and unfractionated heparin in PCI surgery for patients with acute myocardial infarction. Chinese and Foreign Medical Journal. 2023;42:140\u20133+48.","journal-title":"Chinese and Foreign Medical Journal"},{"key":"2782_CR20","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","volume":"400","author":"Y Li","year":"2022","unstructured":"Li Y, Liang Z, Qin L, Wang M, Wang X, Zhang H, et al. Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Lancet. 2022;400:1847\u201357.","journal-title":"Lancet"},{"key":"2782_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.120.008969","volume":"14","author":"S James","year":"2021","unstructured":"James S, Koul S, Andersson J, Anger\u00e5s O, Bhiladvala P, Calais F, et al. Bivalirudin versus heparin monotherapy in ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2021;14: e008969.","journal-title":"Circ Cardiovasc Interv"},{"key":"2782_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008671","volume":"13","author":"A Wester","year":"2020","unstructured":"Wester A, Attar R, Mohammad MA, Isma N, James S, Omerovic E, et al. Bivalirudin versus heparin monotherapy in elderly patients with myocardial infarction: a prespecified subgroup analysis of the VALIDATE-SWEDEHEART trial. Circ Cardiovasc Interv. 2020;13: e008671.","journal-title":"Circ Cardiovasc Interv"},{"key":"2782_CR23","first-page":"101","volume":"6","author":"Y Li","year":"2020","unstructured":"Li Y, Liu P. Comparative study on the efficacy of unfractionated heparin and bivalirudin in patients with acute myocardial infarction undergoing PCI. Smart Health. 2020;6:101\u20132+05.","journal-title":"Smart Health"},{"key":"2782_CR24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1177\/2048872618805663","volume":"8","author":"D Erlinge","year":"2019","unstructured":"Erlinge D, Koul S, Omerovic E, Fr\u00f6bert O, Linder R, Danielewicz M, et al. Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2019;8:492\u2013501.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2782_CR25","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/ccd.27181","volume":"91","author":"C Li","year":"2018","unstructured":"Li C, Xu R, Shen Y, Dai Y, Zhang F, Ma J, et al. Bivalirudin in percutaneous coronary intervention for chronic total occlusion: a single-center pilot study. Catheter Cardiovasc Interv. 2018;91:679\u201385.","journal-title":"Catheter Cardiovasc Interv"},{"key":"2782_CR26","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/ccd.26953","volume":"90","author":"MJ Czarny","year":"2017","unstructured":"Czarny MJ, Hwang CW, Naiman DQ, Lemmon CC, Hasan RK, Wang T, et al. Heparin versus bivalirudin for non-primary percutaneous coronary intervention: a post-hoc analysis of the CPORT-E trial. Catheter Cardiovasc Interv. 2017;90:366\u201377.","journal-title":"Catheter Cardiovasc Interv"},{"key":"2782_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/joic.12462","volume":"31","author":"FV Lima","year":"2018","unstructured":"Lima FV, Gruberg L, Aslam U, Ramgadoo M, Clase K, Trevisan A, et al. The impact of unfractionated heparin or bivalirudin on patients with stable coronary artery disease undergoing percutaneous coronary intervention. J Interv Cardiol. 2018;31:177\u201384.","journal-title":"J Interv Cardiol"},{"key":"2782_CR28","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/ccd.26804","volume":"89","author":"H Wang","year":"2017","unstructured":"Wang H, Li Y, Cong H, Ding S, Liu B, Li L, et al. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: a subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial. Catheter Cardiovasc Interv. 2017;89:1157\u201365.","journal-title":"Catheter Cardiovasc Interv"},{"key":"2782_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ahj.2016.02.007","volume":"175","author":"D Erlinge","year":"2016","unstructured":"Erlinge D, Koul S, Eriksson P, Scherst\u00e9n F, Omerovic E, Linder R, et al. Bivalirudin versus heparin in non-ST and ST-segment elevation myocardial infarction-a registry-based randomized clinical trial in the SWEDEHEART registry (the VALIDATE-SWEDEHEART trial). Am Heart J. 2016;175:36\u201346.","journal-title":"Am Heart J"},{"key":"2782_CR30","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jcin.2014.10.015","volume":"8","author":"C Briguori","year":"2015","unstructured":"Briguori C, Visconti G, Focaccio A, Donahue M, Golia B, Selvetella L, et al. Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting. JACC Cardiovasc Interv. 2015;8:414\u201323.","journal-title":"JACC Cardiovasc Interv"},{"key":"2782_CR31","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1001\/jama.2015.2323","volume":"313","author":"Y Han","year":"2015","unstructured":"Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. JAMA. 2015;313:1336\u201346.","journal-title":"JAMA"},{"key":"2782_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0034-1372244","volume":"23","author":"A Feldman","year":"2014","unstructured":"Feldman A, Suleiman K, Bushari L, Yahalom M, Rozner E, Freedberg NA, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients at high risk for bleeding. Int J Angiol. 2014;23:227\u201332.","journal-title":"Int J Angiol"},{"key":"2782_CR33","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1093\/eurheartj\/ehu182","volume":"35","author":"S Schulz","year":"2014","unstructured":"Schulz S, Richardt G, Laugwitz KL, Morath T, Neudecker J, Hoppmann P, et al. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2014;35:2285\u201394.","journal-title":"Eur Heart J"},{"key":"2782_CR34","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","volume":"384","author":"A Shahzad","year":"2014","unstructured":"Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet. 2014;384:1849\u201358.","journal-title":"Lancet"},{"key":"2782_CR35","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","volume":"369","author":"PG Steg","year":"2013","unstructured":"Steg PG, van \u2019t Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013;369:2207\u201317.","journal-title":"N Engl J Med"},{"key":"2782_CR36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/joic.12005","volume":"26","author":"R Waksman","year":"2013","unstructured":"Waksman R, Bertrand O, Driesman M, Gruberg L, Rossi J, Mehta S, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III). J Interv Cardiol. 2013;26:107\u201313.","journal-title":"J Interv Cardiol"},{"key":"2782_CR37","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.3760\/cma.j.issn.0366-6999.20122569","volume":"126","author":"DC Xiang","year":"2013","unstructured":"Xiang DC, Gu XL, Song YM, Huang WJ, Tang LQ, Yin YH, et al. Evaluation on the efficacy and safety of domestic bivalirudin during percutaneous coronary intervention. Chin Med J (Engl). 2013;126:3064\u20138.","journal-title":"Chin Med J (Engl)"},{"key":"2782_CR38","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.amjcard.2012.04.017","volume":"110","author":"G Patti","year":"2012","unstructured":"Patti G, Pasceri V, D\u2019Antonio L, D\u2019Ambrosio A, Macri M, Dicuonzo G, et al. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the anti-thrombotic strategy for reduction of myocardial damage during angioplasty-bivalirudin vs heparin study). Am J Cardiol. 2012;110:478\u201384.","journal-title":"Am J Cardiol"},{"key":"2782_CR39","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","volume":"365","author":"A Kastrati","year":"2011","unstructured":"Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med. 2011;365:1980\u20139.","journal-title":"N Engl J Med"},{"key":"2782_CR40","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/ccd.22876","volume":"77","author":"DJ Moliterno","year":"2011","unstructured":"Moliterno DJ. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Catheter Cardiovasc Interv. 2011;77:1001\u20139.","journal-title":"Catheter Cardiovasc Interv"},{"key":"2782_CR41","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.amjcard.2009.12.001","volume":"105","author":"G Parodi","year":"2010","unstructured":"Parodi G, Migliorini A, Valenti R, Bellandi B, Signorini U, Moschi G, et al. Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial). Am J Cardiol. 2010;105:1053\u20139.","journal-title":"Am J Cardiol"},{"key":"2782_CR42","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(09)61484-7","volume":"374","author":"R Mehran","year":"2009","unstructured":"Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, et al. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet. 2009;374:1149\u201359.","journal-title":"Lancet"},{"key":"2782_CR43","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S0140-6736(07)60450-4","volume":"369","author":"GW Stone","year":"2007","unstructured":"Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007;369:907\u201319.","journal-title":"Lancet"},{"key":"2782_CR44","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.amjcard.2004.11.021","volume":"95","author":"HS Gurm","year":"2005","unstructured":"Gurm HS, Rajagopal V, Fathi R, Vivekanathan D, Yadav JS, Bhatt DL, et al. Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. Am J Cardiol. 2005;95:716\u201321.","journal-title":"Am J Cardiol"},{"key":"2782_CR45","doi-asserted-by":"publisher","first-page":"5549914","DOI":"10.1155\/cdr\/5549914","volume":"2024","author":"G Wang","year":"2024","unstructured":"Wang G, Qi K, Li X, Zuo S, Zhang R, Zhao Y, et al. Heparin and bivalirudin in percutaneous coronary intervention for acute coronary syndromes: a review article. Cardiovasc Ther. 2024;2024:5549914.","journal-title":"Cardiovasc Ther"},{"key":"2782_CR46","doi-asserted-by":"publisher","first-page":"e44S","DOI":"10.1378\/chest.11-2292","volume":"141","author":"W Ageno","year":"2012","unstructured":"Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S-e88S.","journal-title":"Chest"},{"key":"2782_CR47","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.jcin.2019.06.032","volume":"12","author":"P Capranzano","year":"2019","unstructured":"Capranzano P, Angiolillo DJ. Tug of war between dual and triple antithrombotic therapy in atrial fibrillation\/pci patients with CKD. JACC Cardiovasc Interv. 2019;12:1562\u20135.","journal-title":"JACC Cardiovasc Interv"},{"key":"2782_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114045","volume":"275","author":"Y Li","year":"2021","unstructured":"Li Y, Liu SS, Guo ZY, Yi H, Li C, Chen LM, et al. Discovery of potential pharmacodynamic ingredients of Dang-Gui-Si-Ni decoction based on absorbed ingredients and molecular docking. J Ethnopharmacol. 2021;275: 114045.","journal-title":"J Ethnopharmacol"},{"key":"2782_CR49","doi-asserted-by":"publisher","first-page":"112S","DOI":"10.1592\/phco.22.10.112S.33619","volume":"22","author":"AL Seybert","year":"2002","unstructured":"Seybert AL. Bivalirudin administration during percutaneous coronary intervention: emphasis on high-risk patients. Pharmacotherapy. 2002;22:112S-18S.","journal-title":"Pharmacotherapy"},{"key":"2782_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119\u201377.","journal-title":"Eur Heart J"},{"key":"2782_CR51","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289\u2013367.","journal-title":"Eur Heart J"},{"key":"2782_CR52","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jacc.2021.09.005","volume":"79","author":"JS Lawton","year":"2022","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79:197\u2013215.","journal-title":"J Am Coll Cardiol"},{"key":"2782_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.gheart.2014.03.1976","volume":"9","author":"N Shah","year":"2014","unstructured":"Shah N, Natarajan DK, Rafiudeen R, Ko SK, Taeed A, Soon K, et al. Bivalirudin versus heparin alone in primary PCI for ST-segment elevation myocardial infarction. Glob Heart. 2014;9: e208.","journal-title":"Glob Heart"},{"key":"2782_CR54","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0003-4975(03)00144-9","volume":"76","author":"JN Bott","year":"2003","unstructured":"Bott JN, Reddy K, Krick S. Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia [corrected]. Ann Thorac Surg. 2003;76:273\u20135.","journal-title":"Ann Thorac Surg"},{"key":"2782_CR55","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1161\/ATVBAHA.107.144576","volume":"27","author":"G Li","year":"2007","unstructured":"Li G, Keenan AC, Young JC, Hall MJ, Pamuklar Z, Ohman EM, et al. Effects of unfractionated heparin and glycoprotein IIb\/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol. 2007;27:1850\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2782_CR56","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ijcard.2010.08.007","volume":"152","author":"MS Lee","year":"2011","unstructured":"Lee MS, Liao H, Yang T, Dhoot J, Tobis J, Fonarow G, et al. Comparison of bivalirudin versus heparin plus glycoprotein IIb\/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials. Int J Cardiol. 2011;152:369\u201374.","journal-title":"Int J Cardiol"},{"key":"2782_CR57","first-page":"273","volume":"37","author":"W Xiaowei","year":"2015","unstructured":"Xiaowei W, Wen T, Yi K, Yuelan Z. Relation between ST-segment resolution and proximal prognosis after primary PCI in patients with acute myocardial infarction. Journal of Dalian Medical University. 2015;37:273\u20136.","journal-title":"Journal of Dalian Medical University"},{"key":"2782_CR58","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.hlc.2016.12.019","volume":"26","author":"A Rehmani","year":"2017","unstructured":"Rehmani A, Judkins C, Whelan A, Nguyen M, Schultz C. Comparison of safety and efficacy of unfractionated heparin versus bivalirudin in patients undergoing percutaneous coronary intervention. Heart Lung Circ. 2017;26:1277\u201381.","journal-title":"Heart Lung Circ"},{"key":"2782_CR59","doi-asserted-by":"publisher","first-page":"93","DOI":"10.24018\/ejmed.2021.3.2.768","volume":"3","author":"AG Mostofa","year":"2021","unstructured":"Mostofa AG, Parvin T, Mandal MRM, Afrin R, Ahsan S. Safety and efficacy of bivalirudin in diabetic acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). European Journal of Medical and Health Sciences. 2021;3:93\u20137.","journal-title":"European Journal of Medical and Health Sciences"},{"key":"2782_CR60","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1186\/s12872-024-04399-5","volume":"24","author":"Q Wang","year":"2024","unstructured":"Wang Q, Liu Y, Yang L, Zhou T, Zhang Q, Zhang Z, et al. Reduced-dose of bivalirudin (without the post-procedure infusion) in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. BMC Cardiovasc Disord. 2024;24:713.","journal-title":"BMC Cardiovasc Disord"},{"key":"2782_CR61","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025003","volume":"100","author":"YC Hu","year":"2021","unstructured":"Hu YC, Yao WJ, Jin DX, Zhang JX, Wang L, Zhang R, et al. Bivalirudin in patients undergoing percutaneous coronary intervention and independent predictors of postoperative adverse events in these patients: a real world retrospective study. Medicine. 2021;100: e25003.","journal-title":"Medicine"},{"key":"2782_CR62","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2408218","volume":"24","author":"J Li","year":"2023","unstructured":"Li J, Li Y, Su S, Wang Z, Liu H, Yang W, et al. One-year safety and effectiveness of bivalirudin versus heparin in patients undergoing elective percutaneous coronary intervention. Rev Cardiovasc Med. 2023;24: 218.","journal-title":"Rev Cardiovasc Med"},{"key":"2782_CR63","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.thromres.2015.06.001","volume":"136","author":"S Kianoush","year":"2015","unstructured":"Kianoush S, Bikdeli B, Desai MM, Eikelboom JW. Risk of stent thrombosis and major bleeding with bivalirudin compared with active control: a systematic review and meta-analysis of randomized trials. Thromb Res. 2015;136:1087\u201398.","journal-title":"Thromb Res"},{"key":"2782_CR64","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ahj.2015.10.006","volume":"171","author":"R Shah","year":"2016","unstructured":"Shah R, Rogers KC, Matin K, Askari R, Rao SV. An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention. Am Heart J. 2016;171:14\u201324.","journal-title":"Am Heart J"},{"key":"2782_CR65","first-page":"e344","volume":"130","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines. Circulation. 2014;130:e344-426.","journal-title":"Circulation"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-02782-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-025-02782-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-025-02782-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T09:58:56Z","timestamp":1739181536000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-025-02782-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2782"],"URL":"https:\/\/doi.org\/10.1186\/s13643-025-02782-7","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}